Published: July 2017
Roots Analysis has announced the addition of “Antibody Discovery: Services and Platforms, 2017-2027” report to its list of offerings. The report features an extensive study on the current market landscape and future outlook of antibody discovery services and platform providers.
Pemba Lahmo, the principal analyst, said, “Antibody discovery is an expensive, complex, time consuming and multistep process. The skills and expertise required for the discovery of antibodies are commonly outside the scope of a typical academic laboratory or small company. Hence, these organizations rely on contract research organizations (CROs), which possess specialized technologies and the necessary infrastructure to address the needs of their discovery operations. Additionally, large firms are also turning to CROs for their antibody discovery operations in order to leverage the expertise offered by such organizations and achieve cost savings.”
The report presents an elaborate compilation of research, analysis and opinions on several key aspects of the market. Among other things, the report includes the following:
Lahmo further added, “Driven by the rising demand for targeted therapies and innovation in antibody discovery methods, we expect the antibody discovery services market to witness continuous growth in the coming decade. In terms of geography, more than 70% of the market’s share is distributed between North America and Europe. We believe that China is likely to grow at a faster rate as compared to other regions in the coming decade. With respect to antibody discovery methods, we believe that transgenic animal based methods are likely to grow at a faster rate as compared to the more established methods, such as phage display and hybridoma technology.”
The report highlights the contributions of several players in the field, including those that are listed below:
The opinions and insights discussed in this report were influenced by discussions conducted with industry experts.
The report features detailed transcripts of interviews held with Aaron Sato (Chief Scientific Officer, LakePharma), Christel Iffland (Vice President, Ligand Pharmaceuticals), Debra Valsamis (Business Development Associate, Antibody Solutions), Ignacio Pino (President and CEO, CDI Laboratories), Jeng Her (CEO, AP Biosciences) and Thomas Schirrmann (CEO and General Manager, YUMAB)
For additional details, please visit
We are your partners with no equity
We fit in your budget
We love what we do
Chance to prove ourselves
Best in class quality of work
Most trusted consulting partner in the industry